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AbstrACt
Introduction Both stable chronic obstructive pulmonary 
disease (COPD) and acute exacerbations represent leading 
causes of death, disability and healthcare expenditure. 
They are complex, heterogeneous and their mechanisms 
are poorly understood. The role of respiratory viruses 
has been studied extensively but is still not adequately 
addressed clinically. Through a rigorous evidence update, 
we aim to define the prevalence and clinical burden 
of the different respiratory viruses in stable COPD and 
exacerbations, and to investigate whether viral load of 
usual respiratory viruses could be used for diagnosis of 
exacerbations triggered by viruses, which are currently not 
diagnosed or treated aetiologically.
Methods and analysis Based on a prospectively 
registered protocol, we will systematically review 
the literature using standard methods recommended 
by the Cochrane Collaboration and the Grading of 
Recommendations Assessment, Development and 
Evaluation working group. We will search Medline/
PubMed, Excerpta Medica dataBASE (EMBASE), the 
Cochrane Library, the WHO’s Clinical Trials Registry and 
the proceedings of relevant international conferences 
on 2 March 2020. We will evaluate: (A) the prevalence 
of respiratory viruses in stable COPD and exacerbations, 
(B) differences in the viral loads of respiratory viruses in 
stable COPD vs exacerbations, to explore whether the 
viral load of prevalent respiratory viruses could be used 
as a diagnostic biomarker for exacerbations triggered by 
viruses and (C) the association between the presence of 
respiratory viruses and clinical outcomes in stable COPD 
and in exacerbations.
Ethics and dissemination Ethics approval is not required 
since no primary data will be collected. Our findings 
will be presented in national and international scientific 
conferences and will be published in peer reviewed 
journals. Respiratory viruses currently represent a lost 
opportunity to improve the outcomes of both stable COPD 
and exacerbations. Our work aspires to ‘demystify’ the 
prevalence and clinical burden of viruses in stable COPD 
and exacerbations and to promote clinical and translational 
research.
PrOsPErO registration number CRD42019147658.
IntrOduCtIOn
Chronic obstructive pulmonary disease 
(COPD), a leading cause of death, disability 
and health- related expenditure globally, is 
characterised by chronic debilitating respira-
tory symptoms and acute exacerbations, that 
drive the adverse outcomes of the disease.1–4 
Both stable COPD and exacerbations are 
complex and heterogeneous, meaning 
that several distinct mechanistic pathways 
contribute to their development and progres-
sion.5 6 While some of these pathways are well 
established, our understanding of the pivotal 
strengths and limitations of this study
 ► A holistic approach to a clinically pertinent question 
that could pump- prime clinical and translational 
research and facilitate the introduction of precision 
medicine interventions both for stable chronic ob-
structive pulmonary disease and exacerbations.
 ► A rigorous methodology that includes a thorough 
evaluation of the literature, appropriate evaluation of 
the risk of bias of individual studies and the quality 
of the body of evidence, and quantitative synthesis.
 ► Several planned meta- regression analyses to ex-
plore potential effect modifying factors; however, a 
potential limitation is data may not be available for 
the completion of all these analyses.
 ► A prospectively published protocol increases the 
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role that respiratory viruses appear to have both in stable 
disease and exacerbations is still lacking.
Viruses are identified in over 10% of all patients with 
stable COPD at any given time6 7 8 and in 30%–50% of 
those experiencing exacerbations.9–11 In both cases, 
the presence of viruses is associated with worse clinical 
outcomes.6 7 8 For example, the prevalence and clinical 
implications of viruses were tested longitudinally in a 
subgroup of 127 patients with COPD, who experienced 
355 exacerbations during 1 year of follow- up from the 
Acute Exacerbation and Respiratory InfectionS in COPD 
(AERIS) cohort8 and 83 patients, who experienced 168 
exacerbations during follow- up from the East London 
COPD cohort.7 In the first cohort, viruses were present 
in 13.6% and 41.3% of samples received during stable 
disease and exacerbations, respectively. Almost half of the 
participants (46.5%) had at least one exacerbation that 
tested positive for human rhinovirus (HRV) during 1 year 
of follow- up. In the East London COPD cohort, viruses 
were detected in 39.2% of all exacerbations and were 
associated with higher symptoms burden and delayed 
recovery. The presence of viruses during the stable state 
was associated with more frequent exacerbations.7 In 
general, rhinovirus, influenza and respiratory syncytial 
virus are the most frequently detected and their clinical 
burden has been demonstrated in several studies.7–9 11
Diagnostic techniques for exacerbations triggered by 
respiratory viruses are currently inadequate. Respiratory 
viruses are prevalent both in exacerbations and stable 
COPD. Therefore, the presence of viruses in the airways 
cannot confirm viral aetiology of an exacerbation, since 
viruses may represent incidental findings, rather than the 
real cause of the exacerbation.
Acute respiratory viral infections in healthy people are 
characterised by quick viral replication leading to high 
viral shedding and load that peak rapidly.12 Assuming 
that the same pattern is followed in patients with COPD, 
we would anticipate higher viral loads in exacerbations 
triggered by viruses (not only compared with stable 
COPD, but also compared with exacerbations in which 
viruses are present but not the causative factor). Indeed, 
previous studies have revealed 10- fold higher mean viral 
loads of HRV in exacerbations characterised by symptoms 
consistent with a respiratory viral infection compared 
with stable COPD,10 13 suggesting that viral load might 
be used as a diagnostic biomarker for exacerbations trig-
gered by viruses. Accurate diagnosis of acute exacerba-
tions triggered by viruses could lead to the introduction 
of targeted antiviral treatments that are already commer-
cially available or in development.14 Additionally, it could 
lead to a reduction of the unnecessary administration of 
antibiotics for exacerbations that are triggered by viruses 
(and not by bacteria).15 16
There is an astonishing imbalance between the ample 
published evidence on the prevalence and clinical impact 
of respiratory viruses in COPD and the lack of insight on 
their clinical approach and management. To improve our 
understanding and facilitate the introduction of precision 
medicine interventions for this group of patients, we will 
conduct a systematic review aiming to holistically evaluate:
A. the prevalence of respiratory viruses in patients with 
stable COPD and exacerbations.
B. differences in the viral loads of respiratory viruses in 
stable COPD vs exacerbations, to explore whether vi-
ral loads of prevalent respiratory viruses could be used 
as a gold standard for the diagnosis of exacerbations 
triggered by those viruses.
C. the association between the presence of respiratory 
viruses and clinical outcomes of patients with stable 
COPD and exacerbations.
MEthOds And AnAlysIs
This systematic review and meta- analysis will be based on 
a prospectively registered protocol at the International 
Prospective Register of Systematic Reviews (PROSPERO) 
and it will be conducted following standard methodology 
recommended by the Cochrane Collaboration17 and the 
Grading of Recommendations Assessment, Development, 
and Evaluation (GRADE) working group.18 The Preferred 
Reporting Items for Systematic Reviews and Meta- Analysis 
statement was used for reporting this protocol19 and will 
also be followed for the preparation of the final report of 
this systematic review.20
Eligibility criteria
We will include studies evaluating patients aged over 40 
years with COPD, either during stable disease state or 
exacerbations. We will consider eligible studies evaluating 
stable COPD, provided that participants had a clinical 
diagnosis of COPD, confirmed by spirometry. For studies 
evaluating patients during exacerbations, a previous clin-
ical diagnosis of COPD will suffice. Spirometry during an 
exacerbation has poor specificity, and for this reason, it 
will not be a prerequisite for studies on exacerbations.21 22 
We will exclude studies focusing on specific populations 
who are at high risk of viral infections, such as lung trans-
plant recipients, or people with immune deficiency.
Only studies using molecular techniques to identify 
respiratory viruses will be included. For projects A and 
B (evaluating the prevalence and loads of respiratory 
viruses), we will include studies exploring the prevalence 
of respiratory viruses in representative samples of patients 
with stable COPD or exacerbations. Only studies assessing 
associations between the presence and/or load of respira-
tory viruses and clinical outcomes of COPD or exacerba-
tions will be included in project C.
We will include studies of any design that could 
contribute data pertinent to the review questions. Data 
from randomised controlled trials (RCTs) will be used 
more cautiously compared with observational studies. 
More specifically, we will only include data that are 
unlikely to be affected by investigational medications 
that are not part of the usual care for COPD or exacer-
bations. For example, in a trial evaluating the impact of 
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exacerbations triggered by viruses, we will only capture 
data on the exacerbations’ outcomes from the control 
group. We would capture data on the prevalence and 
loads of respiratory viruses from both study groups, 
provided they were measured prior to the initiation of 
antiviral treatments, in the intervention group.
Outcome measures
Projects A and B: primary outcome: prevalence of respira-
tory viruses in the respiratory tract of patients with stable 
COPD and exacerbations. We will assess individual viruses 
separately, but also the presence of any virus. Secondary 
outcomes: mean viral loads of respiratory viruses during 
stable COPD and exacerbations; seasonal variability in 
the prevalence and viral loads of respiratory viruses and 
proportion of patients testing positive for more than one 
virus. We will also describe the molecular techniques and 
laboratory tests used for identification and quantification 
of respiratory viruses.
For studies evaluating stable COPD, the main analysis 
will only include the first assessment of respiratory viruses 
in every patient. In case of multiple measurements during 
different seasons of the year, we will capture the first 
measurement during every season, to be included in the 
analysis of seasonal variability. For studies evaluating exac-
erbations, the main analysis will include the first assess-
ment of respiratory viruses during every exacerbation. 
The unit of analysis will be the exacerbation, rather than 
the patient. In a sensitivity analysis, we will only include 
the first exacerbation captured for every participant.
Project C: co- primary outcomes for studies evaluating 
stable COPD: annual rate of moderate or severe exacer-
bations and mortality. Secondary outcomes: annual rate 
of severe exacerbations; symptoms severity; health- related 
quality of life; exercise capacity; forced expiratory volume 
in 1 s (FEV1) decline rate.
Co- primary outcomes for studies evaluating exacerba-
tions: mortality and treatment failure rate. Secondary 
outcomes: treatment success rate; symptoms severity; 
symptoms duration; length of hospitalisation; time- to- 
next exacerbation; exacerbations frequency; co- existing 
bacterial infection and proportion of patients who 
received antiviral treatment.
Treatment failure in exacerbations is usually defined as 
a composite outcome, including several of the following 
components: lack of clinical improvement, symptoms 
deterioration, hospital admission, intensive care unit 
admission, need for additional treatments or death.23 
Treatment success is defined as complete resolution or 
significant improvement of the symptoms.23
All clinical outcomes will primarily be evaluated at 
longest follow- up, with the exception of treatment failure 
and treatment success rates in studies evaluating exacer-
bations that will be evaluated at 1–4 weeks from presenta-
tion. In additional analyses of stable COPD studies, we will 
evaluate separately data collected between 0– <3, 3– <6, 
6– <12 and ≥12 months of follow- up. For exacerbations 
studies, in additional analyses, we will assess separately 
data collected between 0– <1, 1– <2, 2– <6 and ≥6 months 
of follow- up, to better capture the early outcomes of 
exacerbations.
systematic literature search
The electronic databases of Medline/PubMed, Excerpta 
Medica dataBASE (EMBASE) and the Cochrane Central 
will be searched on 2 March 2020, using a comprehen-
sive search strategy including appropriate controlled 
vocabulary and free search terms. This strategy was devel-
oped by one author (AGM) and was updated following 
input from all authors and identification of Medical 
Subject Headings (MeSH) terms from several eligible 
studies that were identified during pilot searches. In 
addition to the online databases, we will search for rele-
vant studies in the conference proceedings of the Euro-
pean Respiratory Society, American Thoracic Society and 
Asian Pacific Society of Respirology, European Society of 
Clinical Microbiology and Infectious Diseases, American 
Society of Microbiology, European Society for Clinical 
Virology, in the WHO International Clinical Registry 
Platform and in the reference lists of all included studies 
and all previously published systematic reviews. Detailed 
search strategies are available in the online supplemen-
tary appendix.
Two investigators will independently screen the titles 
and abstracts of all studies that our searches will yield. 
Next, the full- text versions of all potentially eligible manu-
scripts and abstracts will be acquired and reviewed for 
confirmation of eligibility by two authors independently. 
Disagreement in this and all following steps of the system-
atic review process will be resolved by discussion or adju-
dication by a third investigator, when necessary.
data abstraction
Relevant data from each eligible study will be extracted 
in a predefined, pilot- tested excel spreadsheet. The full 
reference of each eligible study, as well as details on the 
study design, eligibility criteria, baseline characteristics, 
details on the viruses evaluated and the performance 
characteristics of laboratory assays used for viral identi-
fication and/or quantification will be extracted by one 
person and will be cross- checked by another person for 
accuracy. Data regarding the prevalence and viral loads 
of respiratory viruses and all clinical outcomes will be 
extracted by two investigators independently. Details on 
all data and variables that will be extracted are available 
in the online supplementary appendix.
Pilot testing of the data extraction form on a sample 
of studies will be conducted by all investigators who will 
subsequently use the form. In case of discrepancies, addi-
tional eligible studies will be extracted until achieving an 
agreement in >95% of the extracted variables among all 
reviewers. Feedback will be sought during this process 
and variables may be added or modified. Missing data 
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risk of bias assessment
For projects A and B, which focus on the prevalence and 
viral loads of viruses in the respiratory tract of patients 
with stable COPD or exacerbations, we will use the risk of 
bias tool for prevalence studies developed by Hoy et al.24 
For project C, we will use the Newcastle- Ottawa Scale.25 
Both tools were developed for assessing the quality of 
non- randomised studies. For this reason, they assess more 
thoroughly the representativeness of the population of 
the included studies.24 25 On the contrary, tools evaluating 
the risk of bias in RCTs focus less on representativeness.17 
However, representativeness of the participants is of 
paramount importance in our meta- analysis, which does 
not focus on the trial interventions. For these reasons, 
we decided to use risk of bias tools for non- randomised 
studies for risk of bias evaluation in studies of any design, 
including RCTs. Risk of bias will be assessed by two inves-
tigators independently. For each study, we will report an 
overall risk of bias assessment, but also our judgement of 
the risk of bias related to each of the domains proposed 
by the selected tools. If we can pool >10 studies, we will 
be able to explore possible small study and publication 
biases by creating and examining a funnel plot and by 
using Egger’s regression and Begg’s rank correlation.17
data synthesis
Heterogeneity among the studies in each meta- analysis 
will be estimated using the I2 statistic. Substantial hetero-
geneity (I2≥50%) will be reported and possible causes will 
be explored by prespecified meta- regression analyses.
In the primary analyses, data will be synthesised using 
a random- effects model because we anticipate signifi-
cant clinical and methodological heterogeneity among 
the included studies. Fixed- effects models will be used in 
sensitivity analyses. The inverse variance method using 
logit transformed proportions will be used for conducting 
meta- analysis of proportions. In the main analyses, indi-
vidual viruses will be evaluated separately. In an addi-
tional analysis, we will evaluate the presence of any virus. 
Meta- analyses will be performed using R statistical soft-
ware (R Foundation for Statistical Computing, Vienna, 
Austria) and the CRAN packages for meta- analysis (meta 
and metafor).
Meta-regression and sensitivity analyses
If adequate data are available, we will conduct meta- 
regression analyses to evaluate the potential impact of the 
following parameters on the outcomes: (1) the season of 
the year when samples were collected; (2) use of inhaled 
corticosteroids; (3) spirometric severity of COPD, classi-
fied based on their FEV1 (≥80%, 50%–80%, 30%–50% or 
<30%); (4) year of study completion and (5) study design 
(observational vs interventional). Additional parameters 
to be tested in project C will include: (6) bacterial co- in-
fection and (7) receipt of antiviral treatment. For each 
of these analyses, we will first attempt to use subgroup 
data from the included studies, if they are available to 
us. Alternatively, we will use the following study- level 
variables for each of the analyses: (1) the proportion of 
samples that were collected during the influenza season; 
(2) the proportion of patients that were using inhaled 
corticosteroids; (3) the mean FEV1 of the participants; 
(4)–(5) same as above; (6) proportion of patients with 
bacterial co- infection and (7) proportion of patients that 
received antiviral treatment. For conducting these anal-
yses, we will use a random- effects model and for meta- 
regression analyses of proportions, we will use the inverse 
variance method with logit transformed proportions. We 
will report the level of significance of the regressions (p 
value) and the correlation coefficients. A risk of type I 
error is introduced since we plan to evaluate the impact of 
seven parameters on the outcomes. To mitigate this risk, 
we will only conduct univariate meta- regression analysis. 
Moreover, we will only confidently assume effect modifi-
cation in cases where the p value is <0.01 and we will only 
consider the possibility of effect modification if p<0.05.
Moreover, we plan to conduct the following sensitivity 
analyses:
a. For analyses focusing on stable COPD, we will only 
include studies which only included participants who 
did not have any exacerbations and had not received 
any oral corticosteroids for at least 3 months prior to 
sampling.
b. For analyses focusing on exacerbations, we will only 
include studies which only included patients with a 
clinical diagnosis of COPD confirmed by spirometry 
during stable state.
c. For analyses focusing on exacerbations, we will only in-
clude studies providing data for only one exacerbation 
per participant.
d. We will repeat meta- analyses using fixed- effects models.
e. We will only include studies of low risk of bias.
Certainty of evidence
For each outcome, we will evaluate the quality of the body 
of evidence using GRADE methodology, which takes into 
consideration study limitations, consistency of the effect, 
imprecision, indirectness, publication bias, magnitude of 
effect, dose response and confounders likely minimising 
the effect.18
Protocol deviations
We will conduct our systematic review according to this 
published protocol. Any deviations will be documented 
and justified in our final report.
Patient and public involvement
This systematic review protocol was developed without 
patient or public involvement.
Ethics and dissemination
Ethical approval is not a requirement since no primary 
data will be collected.
The findings of this systematic review and meta- analysis 
will be presented in national and international scientific 
conferences. They will also be submitted for publication 
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that our findings will facilitate future research and inform 
clinical practice.
dIsCussIOn
Respiratory viral infections represent a major unmet 
treatment need in both stable COPD and exacerbations. 
The planned meta- analyses will systemise the existing 
evidence on their prevalence, clinical burden and—in 
the case of exacerbations—diagnostic techniques.
The prevalence of viral infections in patients with COPD 
exacerbations has been evaluated in two previous system-
atic reviews.26 27 Both had limitations. Only PubMed 
was searched, and the most recent literature search was 
conducted in March 2017. When comparing the studies 
included in each of these reviews, we can see that important 
studies have been missed. Moreover, there is no formal 
assessment of the risk of bias of the included studies. Finally, 
quantitative analyses did not evaluate the prevalence of 
specific viruses, but rather the presence of any virus. To the 
best of our knowledge, the prevalence of viral infections in 
patients with stable COPD and the clinical implications of 
the presence of viruses in either stable COPD or exacerba-
tions has not been previously assessed in a systematic review.
Main strengths of our systematic review include the clini-
cally pertinent review questions, thorough searches of the 
available literature and methodological rigour. The inclu-
sion of several meta- regression and sensitivity analyses will 
improve our confidence on the certainty of our findings. 
Potential unavoidable limitations include the lack of data 
availability on less prevalent viruses (such as metapneumo-
virus, which may not be assessed in many of the available 
studies) and technical limitations of the available studies, 
such as lack of standardisation of the molecular tech-
niques used to identify and quantify respiratory viruses. 
To address technical heterogeneity, we will report on the 
performance characteristics of the molecular techniques 
used. Challenges are anticipated in pooling viral loads, as 
several studies use relative quantification processes with 
little or no normalisation. In the main analysis, evaluating 
the mean viral loads during stable COPD and exacerba-
tions, only studies reporting viral copies will be included. 
In an additional analysis, evaluating the relation of viral 
loads between stable COPD and exacerbations, we will 
also include studies using the same relative quantification 
process for both disease states.
We expect that this work could stimulate clinical and 
translational research, facilitate the introduction of preci-
sion medicine interventions both for stable COPD and 
exacerbations and improve the outcomes of these patients.
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